Background: Deep brain stimulation for obsessive-compulsive disorder (OCD) has targeted several subcortical nuclei, including the subthalamic nucleus (STN) and the nucleus accumbens. While the most appropriate target is still being looked for, little attention has been given to the side of the stimulated hemisphere in relationship to outcome. Methods: We report 2 patients diagnosed with OCD, one having symmetry obsessions and the other one with sexual-religious obsessive thoughts. They were implanted bilaterally with deep electrodes located at both STN and nuclei accumbens. The effectiveness of the stimulation was tested for every possible paired combination of electrodes guided by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score reduction. Results: In both cases, the combination of electrodes which best relieved the OCD symptoms was both the left STN and left accumbens. In case 1, the preoperative Y-BOCS score was 33, and 1 month after stimulation it was 16. In case 2, the Y-BOCS scores were 33 and 3, respectively, with the patient being free of obsessions. Conclusion: Some reports suggest that lesion stimulation or stimulation of only the right side relieves OCD symptoms. However, anatomical and functional studies are not conclusive as to which side is most affected in OCD. Possibly, each OCD patient has an individualized optimal side to stimulate.

Keywords:
Psychiatric surgery, Psychosurgery, Deep brain stimulation, Obsessive-compulsive disorder, Nucleus accumbens stimulation, Subthalamic nucleus stimulation, Personalized target
1.
De Koning PP, Figee M, van den Munckhof P, Schuurman PR, Denys D: Current status of deep brain stimulation for obsessive-compulsive disorder: a clinical review of different targets. Curr Psychiatry Rep 2011;13:274-282.
2.
Lipsman N, Neimat J, Lozano AM: Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: the search for a valid target. Neurosurgery 2007;61:1-11, discussion 11-13.
3.
Denys D, Mantione M, Figee M, van den Munckhof P, Koerselman F, Westenberg H, Bosch A, Schuurman R: Deep brain stimulation of the nucleus accumbens for treatment-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2010;67:1061-1068.
4.
Sturm V, Lenartz D, Koulousakis A, Treuer H, Herholz K, Klein JC, Klosterkötter J: The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsive- and anxiety-disorders. J Chem Neuroanat 2003;26:293-299.
5.
Huff W, Lenartz D, Schormann M, Lee SH, Kuhn J, Koulousakis A, Mai J, Daumann J, Maarouf M, Klosterkötter J, Sturm V: Unilateral deep brain stimulation of the nucleus accumbens in patients with treatment-resistant obsessive-compulsive disorder: outcomes after one year. Clin Neurol Neurosurg 2010;112:137-143.
6.
Mallet L, Polosan M, Jaafari N, Baup N, Welter ML, Fontaine D, du Montcel ST, Yelnik J, Chéreau I, Arbus C, Raoul S, Aouizerate B, Damier P, Chabardès S, Czernecki V, Ardouin C, Krebs MO, Bardinet E, Chaynes P, Burbaud P, Cornu P, Derost P, Bougerol T, Bataille B, Mattei V, Dormont D, Devaux B, Vérin M, Houeto JL, Pollak P, Benabid AL, Agid Y, Krack P, Millet B, Pelissolo A; STOC Study Group: Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med 2008;359:2121-2134. Erratum in: N Engl J Med 2009;361:1027.
7.
Lewin AB, De Nadai AS, Park J, Goodman WK, Murphy TK, Storch EA: Refining clinical judgment of treatment outcome in obsessive-compulsive disorder. Psychiatry Res 2011;185:394-401.
8.
Lippitz BE, Mindus P, Meyerson BA, Kihlstrom L, Lindquist C: Lesion topography and outcome after thermocapsulotomy or gamma knife capsulotomy for obsessive-compulsive disorder: relevance of the right hemisphere. Neurosurgery 1999;44:452-458.
9.
Riestra AR, Aguilar J, Zambito G, Galindo y Villa G, Barrios F, García C, Heilman KM: Unilateral right anterior capsulotomy for refractory major depression with comorbid obsessive-compulsive disorder. Neurocase 2011;17:491-500.
10.
Spielberg JM, Miller GA, Engels AS, Herrington JD, Sutton BP, Banich MT, Heller W: Trait approach and avoidance motivation: lateralized neural activity associated with executive function. Neuroimage 2011;54:661-670.
11.
Baxter LR Jr, Phelps ME, Mazziotta JC, Guze BH, Schwartz JM, Selin CE: Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry 1987;44:211-218.
12.
Tot S, Ozge A, Cömelekoğlu U, Yazici K, Bal N: Association of QEEG findings with clinical characteristics of OCD: evidence of left frontotemporal dysfunction. Can J Psychiatry 2002;47:538-545.
13.
Christian CJ, Lencz T, Robinson DG, Burdick KE, Ashtari M, Malhotra AK, Betensky JD, Szeszko PR: Gray matter structural alterations in obsessive-compulsive disorder: relationship to neuropsychological functions. Psychiatry Res 2008;164:123-131.
14.
Wobrock T, Gruber O, McIntosh AM, Kraft S, Klinghardt A, Scherk H, Reith W, Schneider-Axmann T, Lawrie SM, Falkai P, Moorhead TW: Reduced prefrontal gyrification in obsessive-compulsive disorder. Eur Arch Psychiatry Clin Neurosci 2010;260:455-464.
15.
Crespo-Facorro B, Cabranes JA, López-Ibor Alcocer MI, Payá B, Fernández Pérez C, Encinas M, Ayuso Mateos JL, López-Ibor JJ Jr: Regional cerebral blood flow in obsessive-compulsive patients with and without a chronic tic disorder. A SPECT study. Eur Arch Psychiatry Clin Neurosci 1999;249:156-161.
16.
Baxter LR Jr, Schwartz JM, Phelps ME, Mazziotta JC, Guze BH, Selin CE, Gerner RH, Sumida RM: Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry 1989;46:243-250.
17.
Killgore WD, Gruber SA, Yurgelun-Todd DA: Depressed mood and lateralized prefrontal activity during a Stroop task in adolescent children. Neurosci Lett 2007;416:43-48.
18.
Herrington JD, Heller W, Mohanty A, Engels AS, Banich MT, Webb AG, Miller GA: Localization of asymmetric brain function in emotion and depression. Psychophysiology 2010;47:442-454.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.